Literature DB >> 9028350

p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations.

G Coggi1, S Bosari, M Roncalli, D Graziani, P Bossi, G Viale, R Buffa, S Ferrero, M Piazza, S Blandamura, A Segalin, L Bonavina, A Peracchia.   

Abstract

BACKGROUND: p53 gene mutation and p53 protein accumulation are common in human cancer. However, their clinical significance is controversial and p53 accumulation may not correlate with gene mutation. The current study investigates the occurrence of p53 alterations in esophageal carcinoma, the correlation between the analyses at the gene and protein level, and their prognostic significance.
METHODS: A series of 74 esophageal carcinomas (46 squamous cell carcinomas, 21 Barrett's adenocarcinomas, and 7 undifferentiated carcinomas) was studied by single strand conformation polymorphism (SSCP) analysis and immunohistochemistry (IHC) to detect p53 mutation and accumulation, respectively.
RESULTS: p53 mutations in exons 5-8 were detected in 53% of the carcinomas whereas p53 accumulation was observed in 57% of cases. Comparing SSCP and IHC, there were 27 discordant cases (38%). Overall, only 20 tumors (27%) did not display p53 mutation and/or p53 accumulation. No associations were found between p53 aberrations and clinicopathologic parameters, including patients age and gender tumor type, stage, and grade. p53 protein accumulation and p53 gene mutation were not related to patient survival by univariate or multivariate analysis in esophageal carcinomas.
CONCLUSIONS: p53 aberrations are very common in esophageal carcinomas. However, p53 gene mutation and p53 protein accumulation have a significant discordance, suggesting that p53 function may be inactivated by mechanisms other than mutation. p53 aberrations do not independently predict prognosis in esophageal tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028350     DOI: 10.1002/(sici)1097-0142(19970201)79:3<425::aid-cncr1>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma.

Authors:  Asuka Murata; Yoshifumi Baba; Masayuki Watanabe; Hironobu Shigaki; Keisuke Miyake; Ryuichi Karashima; Yu Imamura; Satoshi Ida; Takatsugu Ishimoto; Shiro Iwagami; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

4.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

5.  Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!

Authors:  S L Preston; J A Jankowski
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

6.  Predictive factors of coexisting cancer in Barrett's high-grade dysplasia.

Authors:  C Tharavej; J A Hagen; J H Peters; G Portale; J Lipham; S R DeMeester; C G Bremner; T R DeMeester
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

7.  The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.

Authors:  Yukiharu Hiyoshi; Naoya Yoshida; Masayuki Watanabe; Junji Kurashige; Yoshifumi Baba; Yasuo Sakamoto; Hideo Baba
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

8.  p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.

Authors:  A G Casson; M Tammemagi; S Eskandarian; M Redston; J McLaughlin; H Ozcelik
Journal:  Mol Pathol       Date:  1998-04

9.  Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.

Authors:  Zhong-Zheng Zhu; Bing Liu; Ai-Zhong Wang; Hang-Ruo Jia; Xia-Xiang Jin; Xiang-Lei He; Li-Fang Hou; Guan-Shan Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

10.  Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.

Authors:  Jonine D Figueroa; Mary Beth Terry; Marilie D Gammon; Thomas L Vaughan; Harvey A Risch; Fang-Fang Zhang; David E Kleiner; William P Bennett; Christine L Howe; Robert Dubrow; Susan T Mayne; Joseph F Fraumeni; Wong-Ho Chow
Journal:  Cancer Causes Control       Date:  2008-11-07       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.